The company removed experimental drugs for Alzheimer’s, migraine and pain from its pipeline to focus more resources on “core ...

A new commercial for AstraZeneca’s Truqap constructs a vision of the extra time that the AKT inhibitor can unlock for some ...

Q1 2025 Earnings Call Transcript April 29, 2025 AstraZeneca PLC beats earnings expectations. Reported EPS is $1.3, ...

European stocks closed higher on Wednesday, as investors pored through another slew of earnings and reacted to ...

Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

CEO Albert Bourla is waiting for the US government to finalize its decision on whether to place a 25% tariff on ...

AstraZeneca has come up short in another phase 3 trial of the AKT inhibitor Truqap, raising more questions about the ...

Soriot discussed the impact of potential tariffs during a call on AstraZeneca's earnings. For the three months ended March 31, during which period the firm netted $13.59 billion in total revenue, an ...

CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on pharmaceuticals and said ...

Discover AstraZeneca's Q1 2025 performance with 10% revenue growth, innovative medicines, and bold 2030 goals.

Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro ...

AstraZeneca expects only limited impact from potential U.S. tariffs on pharmaceutical imports, the drugmaker said on Tuesday, ...